Amid concerns surrounding Sputnik V and the launch of a single-dose vaccine, Indian companies, including Hetero, Stelis, Biopharma and Gland Pharma are on track to make millions of doses of the Russian vaccine in a bid to alleviate the country's supply constraints
Vamsi Krishna Bandi (left), managing director of Hetero Group of Companies, and his father Bandi Parthasaradhi Reddy, founder and chairman of Hetero Group of Companies
Image: Vikas Chandra Pureti for Forbes India
Vamsi Krishna Bandi knows the importance of staying relevant. In fact, he has an appetite for it. After all, his father, Dr Bandi Parthasaradhi (BPS) Reddy, the first employee of Hyderabad-based Dr Reddy’s Laboratories, had quit the company as chief technologist in 1993 when he realised that a change in management could curtail his future in the company. BPS Reddy, a scientist with a doctorate in synthetic chemistry, was a close confidante of Dr K Anji Reddy, the erstwhile founder and chairman of Dr Reddy’s, and was the man in charge of operational functions at the pharmaceutical company by the time he was in his mid-30s.
(This story appears in the 04 June, 2021 issue of Forbes India. To visit our Archives, click here.)